Production of [ 211 At]NaAt solution under GMP compliance for investigator-initiated clinical trial.

Sadahiro NakaKazuhiro OoeYoshifumi ShirakamiKenta KurimotoToshihiro SakaiKazuhiro TakahashiAtsushi ToyoshimaYang WangHiromitsu HabaHiroki KatoNoriyuki TomiyamaTadashi Watabe

Published in: EJNMMI radiopharmacy and chemistry (2024)

At]NaAt solution that can be administered to humans intravenously as an investigational product.

Keyphrases

clinical trial
phase ii
solid state
biofilm formation
double blind
cystic fibrosis
staphylococcus aureus
pseudomonas aeruginosa
candida albicans